Related Experiment Video
Updated: Aug 4, 2026
Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
Published on: February 6, 2015
Approaches to preclinical screening of antiangiogenic agents
E A Kruger1, P H Duray, D K Price
1Medicine Branch, Cancer Therapy Evaluation Program, National Cancer Institute, Bldg. 10., Room 5A01, 10 Center Dr., Bethesda, MD 20892, USA.
Abstract:
Angiogenesis, or new blood vessel growth, is essential for the growth, invasion, and metastasis of solid tumors. The inhibition of this process, or antiangiogenesis, is a promising new therapeutic anticancer strategy. Several antiangiogenic compounds are currently in preclinical or clinical development for the treatment of cancer. However, the challenge for the discovery and characterization of antiangiogenic targets remains in developing efficient in vitro or in vivo preclinical angiogenesis screening assays to assess and compare antiangiogenic activity. Several semiquantitative or quantitative angiogenesis assays exist, including in vitro endothelial cell systems and ex vivo or in vivo neovascularization models utilizing mouse, rat, or human tissues. We describe the more common and cost-effective angiogenesis assays currently in use, summarizing their unique advantages and disadvantages. Since angiogenesis inhibition is a novel therapeutic modality towards controlling solid tumors, antiangiogenic drug development underlines the importance in describing, standardizing, and developing quantitative screening assays for the next generation of antiangiogenic agents.
Insights
Developing effective antiangiogenesis screening assays is crucial for advancing new cancer therapies. This study reviews common assays to aid in selecting the best methods for antiangiogenic drug discovery.
Area of Science:
- Oncology
- Biomedical Research
- Drug Discovery
Background:
- Angiogenesis (new blood vessel growth) fuels tumor progression, invasion, and metastasis.
- Antiangiogenesis, the inhibition of blood vessel formation, is a key anticancer strategy.
- Numerous antiangiogenic compounds are in preclinical and clinical development.
Purpose of the Study:
- To address the challenge of discovering and characterizing antiangiogenic targets.
- To evaluate the efficiency of in vitro and in vivo preclinical angiogenesis screening assays.
- To compare the antiangiogenic activity assessed by various assays.
Main Methods:
- Review of common semiquantitative and quantitative angiogenesis assays.
- Inclusion of in vitro endothelial cell systems.
- Inclusion of ex vivo and in vivo neovascularization models using rodent and human tissues.
Main Results:
- Description of the advantages and disadvantages of various cost-effective angiogenesis assays.
- Summary of current preclinical screening methodologies for antiangiogenic compounds.
Conclusions:
- Standardization and development of quantitative screening assays are vital for next-generation antiangiogenic agents.
- Efficient assays are essential for advancing antiangiogenic drug development and cancer therapy.
More Related Videos
09:20Preclinical Assessment of the Bioactivity of the Anticancer Coumarin OT48 by Spheroids, Colony Formation Assays, and Zebrafish Xenografts
Published on: June 26, 2018
08:04In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
Published on: May 11, 2021
